Pharmacoeconomics of empirical antifungal use in febrile neutropenic hematological malignancy and hematopoietic stem cell transplant patients

References

• Nivoix Y, Velten M, Letscher-Bru V et al. Factors associated with overall and attributable mortality in invasive aspergillosis. Clin. Infect. Dis. 47(9), 1176–1184 (2008).
   PubMed Web of Science ®Google Scholar
• Kurosawa M, Yonezumi M, Hashino S et al. Epidemiology and treatment outcome of invasive fungal infections in patients with hematological malignancies. Int. J. Hematol. 96(6), 748–757 (2012).
   PubMed Web of Science ®Google Scholar
• Upton A, Kirby KA, Carpenter P, Boeckh M, Marr KA. Invasive aspergillosis following hematopoietic cell transplantation: outcomes and prognostic factors associated with mortality. Clin. Infect. Dis. 44(4), 531–540 (2007).
   PubMed Web of Science ®Google Scholar
• Pagano L, Caira M, Candoni A et al. The epidemiology of fungal infections in patients with hematologic malignancies: the SEIFEM-2004 study. Haematologica 91(8), 1068–1075 (2006).
   PubMed Web of Science ®Google Scholar
• Pagano L, Caira M, Nosari A et al. Fungal infections in recipients of hematopoietic stem cell transplants: results of the SEIFEM B-2004 study – Sorveglianza Epidemiologica Infezioni Fungine Nelle Emopatie Maligne. Clin. Infect. Dis. 45(9), 1161–1170 (2007).
   PubMed Web of Science ®Google Scholar
• Neofytos D, Horn D, Anaissie E et al. Epidemiology and outcome of invasive fungal infection in adult hematopoietic stem cell transplant recipients: analysis of Multicenter Prospective Antifungal Therapy (PATH) Alliance registry. Clin. Infect. Dis. 48(3), 265–273 (2009).
   PubMed Web of Science ®Google Scholar
• Slavin M, Fastenau J, Sukarom I, Mavros P, Crowley S, Gerth WC. Burden of hospitalization of patients with Candida and Aspergillus infections in Australia. Int. J. Infect. Dis. 8(2), 111–120 (2004).
   PubMed Web of Science ®Google Scholar
• Walsh TJ, Pappas P, Winston DJ et al.; National Institute of Allergy and Infectious Diseases Mycoses Study Group. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N. Engl. J. Med. 346(4), 225–234 (2002).
   PubMed Web of Science ®Google Scholar
• Rüping MJ, Vehreschild JJ, Cornely OA. Patients at high risk of invasive fungal infections: when and how to treat. Drugs 68(14), 1941–1962 (2008).
   PubMed Web of Science ®Google Scholar
• Kriengkauykiat J, Ito JI, Dadwal SS. Epidemiology and treatment approaches in management of invasive fungal infections. Clin. Epidemiol. 3, 175–191 (2011).
   PubMedGoogle Scholar
• McCormack PL, Perry CM. Caspofungin: a review of its use in the treatment of fungal infections. Drugs 65(14), 2049–2068 (2005).
   PubMed Web of Science ®Google Scholar
• Bow EJ. Neutropenic fever syndromes in patients undergoing cytotoxic therapy for acute leukemia and myelodysplastic syndromes. Semin. Hematol. 46(3), 259–268 (2009).
   Google Scholar
• Zaragoza R, Pemán J, Salavert M et al. Multidisciplinary approach to the treatment of invasive fungal infections in adult patients. Prophylaxis, empirical, preemptive or targeted therapy, which is the best in the different hosts? Ther. Clin. Risk Manag. 4(6), 1261–1280 (2008).
   PubMedGoogle Scholar
• Marchetti O, Cordonnier C, Calandra T. Empirical antifungal therapy in neutropaenic cancer patients with persistent fever. EJC Suppl. 5, 32–42 (2007).
   Google Scholar
• Freifeld AG, Bow EJ, Sepkowitz KA et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. Clin. Infect. Dis. 52(4), e56–e93 (2011).
   PubMed Web of Science ®Google Scholar
• Ferrara JJ, MacDougall C, Gallagher JC. Empiric antifungal therapy in patients with febrile neutropenia. Pharmacotherapy 31(4), 369–385 (2011).
   PubMed Web of Science ®Google Scholar
• Rüping MJ, Vehreschild JJ, Groll A et al. Current issues in the clinical management of invasive aspergillosis – the AGIHO, DMykG, ÖGMM and PEG web-based survey and expert consensus conference 2009. Mycoses 54(5), e557–e568 (2011).
   Google Scholar
• Walsh TJ, Teppler H, Donowitz GR et al. Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N. Engl. J. Med. 351(14), 1391–1402 (2004).
   PubMed Web of Science ®Google Scholar
• Oakley KL, Moore CB, Denning DW. In-vitro activity of voriconazole against Aspergillus spp. and comparison with itraconazole and amphotericin B. J. Antimicrob. Chemother. 42(1), 91–94 (1998).
   PubMed Web of Science ®Google Scholar
• Tabosa Do Egito E, Appel M, Fessi H, Barratt G, Puisieux F, Devissaguet J-P. In-vitro and in-vivo evaluation of a new amphotericin B emulsion-based delivery system. J. Antimicrob. Chemother. 38(3), 485–497 (1996).
   Google Scholar
• Földi R, Kovács R, Gesztelyi R et al. Comparison of in vitro and vivo efficacy of caspofungin against Candida parapsilosis, C. orthopsilosis, C. metapsilosis and C. albicans. Mycopathologia 174(4), 311–318 (2012).
   PubMedGoogle Scholar
• Walsh TJ, Finberg RW, Arndt C et al. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group. N. Engl. J. Med. 340(10), 764–771 (1999).
   PubMed Web of Science ®Google Scholar
• Wingard JR, White MH, Anaissie E, Raffalli J, Goodman J, Arrieta A; L Amph/ABLC Collaborative Study Group. A randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia. L Amph/ABLC Collaborative Study Group. Clin. Infect. Dis. 31(5), 1155–1163 (2000).
   PubMed Web of Science ®Google Scholar
• Boogaerts M, Winston DJ, Bow EJ et al.; Itraconazole Neutropenia Study Group. Intravenous and oral itraconazole versus intravenous amphotericin B deoxycholate as empirical antifungal therapy for persistent fever in neutropenic patients with cancer who are receiving broad-spectrum antibacterial therapy. A randomized, controlled trial. Ann. Intern. Med. 135(6), 412–422 (2001).
   PubMed Web of Science ®Google Scholar
• Schuler U, Bammer S, Aulitzky WE et al. Safety and efficacy of itraconazole compared to amphotericin B as empirical antifungal therapy for neutropenic fever in patients with haematological malignancy. Onkologie 30(4), 185–191 (2007).
   PubMedGoogle Scholar
• Brielmaier BD, Casabar E, Kurtzeborn CM, McKinnon PS, Ritchie DJ. Early clinical experience with anidulafungin at a large tertiary care medical center. Pharmacotherapy 28(1), 64–73 (2008).
   PubMed Web of Science ®Google Scholar
• Kubiak DW, Bryar JM, McDonnell AM et al. Evaluation of caspofungin or micafungin as empiric antifungal therapy in adult patients with persistent febrile neutropenia: a retrospective, observational, sequential cohort analysis. Clin. Ther. 32(4), 637–648 (2010).
   PubMed Web of Science ®Google Scholar
• Maertens J, Marchetti O, Herbrecht R et al.; Third European Conference on Infections in Leukemia. European guidelines for antifungal management in leukemia and hematopoietic stem cell transplant recipients: summary of the ECIL 3 – 2009 update. Bone Marrow Transplant. 46(5), 709–718 (2011).
   PubMed Web of Science ®Google Scholar
• Coukell AJ, Brogden RN. Liposomal amphotericin B. Therapeutic use in the management of fungal infections and visceral leishmaniasis. Drugs 55(4), 585–612 (1998).
   PubMed Web of Science ®Google Scholar
• Moen MD, Lyseng-Williamson KA, Scott LJ. Liposomal amphotericin B: a review of its use as empirical therapy in febrile neutropenia and in the treatment of invasive fungal infections. Drugs 69(3), 361–392 (2009).
   PubMed Web of Science ®Google Scholar
• Eiden C, Peyrière H, Cociglio M et al.; Network of the French Pharmacovigilance Centers. Adverse effects of voriconazole: analysis of the French Pharmacovigilance Database. Ann. Pharmacother. 41(5), 755–763 (2007).
   PubMed Web of Science ®Google Scholar
• Metzke B, Neubauer WC, Hieke S, Jung M, Wäsch R, Engelhardt M. Use of systemic antifungals in daily clinical practice in the haematology and oncology setting: results of a prospective observational analysis. Pharmacoepidemiol. Drug Saf. 21(9), 953–963 (2012).
   Google Scholar
• Jacobs F, Selleslag D, Aoun M, Sonet A, Gadisseur A. An observational efficacy and safety analysis of the treatment of acute invasive aspergillosis using voriconazole. Eur. J. Clin. Microbiol. Infect. Dis. 31(6), 1173–1179 (2012).
   PubMed Web of Science ®Google Scholar
• Jeu L, Piacenti FJ, Lyakhovetskiy AG, Fung HB. Voriconazole. Clin. Ther. 25(5), 1321–1381 (2003).
   PubMed Web of Science ®Google Scholar
• Przepiorka D, Buadi FK, McClune B. Oral voriconazole for empiric antifungal treatment in patients with uncomplicated febrile neutropenia. Pharmacotherapy 28(1), 58–63 (2008).
   PubMed Web of Science ®Google Scholar
• Jørgensen K, Gøtzsche P, Johansen H. Voriconazole versus amphotericin B in cancer patients with neutropenia. Cochrane Database of Syst. Rev. 1, CD004707 (2006).
   Google Scholar
• Dixon S, McKeen E, Tabberer M, Paisley S. Economic evaluations of treatments for systemic fungal infections: a systematic review of the literature. Pharmacoeconomics 22(7), 421–433 (2004).
   PubMed Web of Science ®Google Scholar
• Playford EG, Lipman J, Sorrell TC. Prophylaxis, empirical and preemptive treatment of invasive candidiasis. Curr. Opin. Crit. Care 16(5), 470–474 (2010).
   Google Scholar
• Freemantle N, Tharmanathan P, Herbrecht R. Systematic review and mixed treatment comparison of randomized evidence for empirical, pre-emptive and directed treatment strategies for invasive mould disease. J. Antimicrob. Chemother. 66(Suppl. 1), i25–i35 (2011).
   Google Scholar
• Al-Badriyeh D, Liew D, Stewart K, Kong DC. Cost–effectiveness evaluation of voriconazole versus liposomal amphotericin B as empirical therapy for febrile neutropenia in Australia. J. Antimicrob. Chemother. 63(1), 197–208 (2009).
   PubMed Web of Science ®Google Scholar
• Al-Badriyeh D, Liew D, Stewart K, Kong DC. Economic impact of caspofungin as compared with liposomal amphotericin B for empirical therapy in febrile neutropenia in Australia. J. Antimicrob. Chemother. 63(6), 1276–1285 (2009).
   PubMed Web of Science ®Google Scholar
• Al-Badriyeh D, Liew D, Stewart K, Kong DC. Pharmacoeconomic analysis of voriconazole vs. caspofungin in the empirical antifungal therapy of febrile neutropenia in Australia. Mycoses 55(3), 244–256 (2012).
   Google Scholar
• Bruynesteyn K, Gant V, McKenzie C et al. A cost–effectiveness analysis of caspofungin vs. liposomal amphotericin B for treatment of suspected fungal infections in the UK. Eur. J. Haematol. 78(6), 532–539 (2007).
   PubMed Web of Science ®Google Scholar
• Collins CD, Stuntebeck ER, DePestel DD, Stevenson JG. Pharmacoeconomic analysis of liposomal amphotericin B versus voriconazole for empirical treatment of febrile neutropenia. Clin. Drug Investig. 27(4), 233–241 (2007).
   PubMed Web of Science ®Google Scholar
• Kaskel P, Tuschy S, Wagner A et al. Economic evaluation of caspofungin vs liposomal amphotericin B for empirical therapy of suspected systemic fungal infection in the German hospital setting. Ann. Hematol. 87(4), 311–319 (2008).
   PubMed Web of Science ®Google Scholar
• Stam WB, Aversa F, Kumar RN, Jansen JP. Economic evaluation of caspofungin versus liposomal amphotericin B for empiric antifungal treatment in patients with neutropenic fever in Italy. Value Health 11(5), 830–841 (2008).
   PubMed Web of Science ®Google Scholar
• Wingard JR, Leather HL, Wood CA et al. Pharmacoeconomic analysis of caspofungin versus liposomal amphotericin B as empirical antifungal therapy for neutropenic fever. Am. J. Health. Syst. Pharm. 64(6), 637–643 (2007).
   PubMed Web of Science ®Google Scholar
• Naik S, Lundberg J, Kumar R, Sjolin J, Jansen J. Economic evaluation of caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia in Sweden. Scand. J. Infect. Dis. 43(6–7), 504–514 (2011).
   PubMed Web of Science ®Google Scholar
• Romá-Sánchez E, Poveda-Andrés JL, García-Pellicer J, Salavert-Lletí M, Jarque-Ramos I. Cost–effectiveness analysis of the empirical antifungal strategy in oncohaematological patients. Farm. Hosp. 32(1), 7–17 (2008).
   PubMedGoogle Scholar
• Shehab N, DePestel DD, Mackler ER, Collins CD, Welch K, Erba HP. Institutional experience with voriconazole compared with liposomal amphotericin B as empiric therapy for febrile neutropenia. Pharmacotherapy 27(7), 970–979 (2007).
   PubMedGoogle Scholar
• Rubio-Terrés C, Grau S. Pharmacoeconomics of voriconazole. Expert Opin. Pharmacother. 11(6), 877–887 (2010).
   PubMed Web of Science ®Google Scholar
• de Pauw BE, Sable CA, Walsh TJ et al. Impact of alternate definitions of fever resolution on the composite endpoint in clinical trials of empirical antifungal therapy for neutropenic patients with persistent fever: analysis of results from the Caspofungin Empirical Therapy Study. Transpl. Infect. Dis. 8(1), 31–37 (2006).
   PubMed Web of Science ®Google Scholar
• Revicki DA, Lenderking WR. Methods and issues associated with the use of quality-adjusted life-years. Expert Rev. Pharmacoecon. Outcomes Res. 12(1), 105–114 (2012).
   PubMed Web of Science ®Google Scholar
• Morrissey CO, Chen SC, Sorrell TC et al. Design issues in a randomized controlled trial of a pre-emptive versus empiric antifungal strategy for invasive aspergillosis in patients with high-risk hematologic malignancies. Leuk. Lymphoma 52(2), 179–193 (2011).
   PubMed Web of Science ®Google Scholar
• van der Linden JW, Jansen RR, Bresters D et al. Azole-resistant central nervous system aspergillosis. Clin. Infect. Dis. 48(8), 1111–1113 (2009).
   Google Scholar
• Mikolajewska A, Schwartz S, Ruhnke M. Antifungal treatment strategies in patients with haematological diseases or cancer: from prophylaxis to empirical, pre-emptive and targeted therapy. Mycoses 55(1), 2–16 (2012).
   PubMed Web of Science ®Google Scholar
• Ostrosky-Zeichner L, Casadevall A, Galgiani JN, Odds FC, Rex JH. An insight into the antifungal pipeline: selected new molecules and beyond. Nat. Rev. Drug Discov. 9(9), 719–727 (2010).
   PubMed Web of Science ®Google Scholar
• Rojas R, Molina JR, Jarque I et al. Outcome of antifungal combination therapy for invasive mold infections in hematological patients is independent of the chosen combination. Mediterr. J. Hematol. Infect. Dis. 4(1), e2012011 (2012).
   PubMedGoogle Scholar
• Baddley JW, Pappas PG. Antifungal combination therapy: clinical potential. Drugs 65(11), 1461–1480 (2005).
   PubMed Web of Science ®Google Scholar
• Marr K, Schlamm H, Rottinghaus S et al. A randomized, double-blind study of combination antifungal therapy with voriconazole and anidulafungin versus voriconazole monotherapy for primary treatment of invasive aspergillosis. Presented at: 22nd European Congress of Clinical Microbiology and Infectious Diseases. Congrex, Switzerland Ltd., London, UK, 31 March–3 April 2012.
   Google Scholar